arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Shattuck Labs, Inc.

STTK
$6.37 ▼ -0.16 (-2.45%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Shattuck Labs, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $826.7M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -6.0% ↗
FCF / Share $-0.08 ↗
Trailing P/E —
Price / Book 3.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-14.77M
↓ -7.8% —
Operating Margin Operating profit as % of sales
30.7%
↑ +106.3% —
FCF / Share Free cash flow per share
$-0.08
↑ +34.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
14
Cash Quality ↓
55

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters